TGU Varimol - 24/07/2020 Click chemistry for new medical procedures Using a simple molecular click process, biochemists have been able to connect ring-shaped molecules with each other and couple therapeutically active substances to these molecules. Drugs can thus be specifically delivered to diseased cells and used for imaging processes or biosensors. The Stuttgart-based start-up Varimol is using this new technology to provide its customers with tailored applications that are as simple to use as a kit.https:////www.gesundheitsindustrie-bw.de/en/article/news/click-chemistry-new-medical-procedures
Microstructure Technology - 17/07/2020 An electronic nose for many applications Sensory organs are sophisticated masterpieces of nature. That is why humans have often tried to copy them. Be it cameras or microphones - there are technical objects that have always been based on natural models such as the eye or the ear. For a long time, however, no artificial sense of smell has featured in the technical repertoire. Now researchers at the Karlsruhe Institute of Technology (KIT) have developed an electronic nose. It can…https:////www.gesundheitsindustrie-bw.de/en/article/news/electronic-nose-many-applications
SICOS BW GmbH - 18/06/2020 High-performance computing and data analytics to combat coronavirus In an epidemic, data exchange and the use of innovative technologies are essential to be able to act effectively and quickly against the infection. High-performance computers and data analytics make a valuable contribution to this. SICOS BW is a promising solution centre that bridges the gap from numerical simulation, big data and AI to companies in the medical technology sector.https:////www.gesundheitsindustrie-bw.de/en/article/news/high-performance-computing-and-data-analytics-to-combat-coronavirus
Press release - 07/05/2020 Privacy-aware Corona Tracing App Identification of contacts is one of the most important measures to mitigate the spread of the Corona virus. Tracing apps are to help. Technical implementation, however, is associated with the risk of data misuse and the approaches presented so far do not sufficiently protect privacy. Researchers of Karlsruhe Institute of Technology (KIT) and of the FZI Research Center for Information Technology have now proposed an app that enhances privacy.https:////www.gesundheitsindustrie-bw.de/en/article/press-release/datenschutzfreundliche-corona-tracing-app
Article - 24/01/2019 Scientists to combat antibiotic-resistant bacteria in wastewater In Germany, around 1,500 tonnes of antibiotics per year are administered to humans and animals. As a result, more and more bacteria are developing resistance to common antibiotics. As part of HyReKA, a cooperative project funded by the BMBF, scientists led by Professor Thomas Schwartz from the KIT are investigating how antibiotic-resistant pathogens spread and how they can be prevented from doing so.https:////www.gesundheitsindustrie-bw.de/en/article/news/scientists-to-combat-antibiotic-resistant-bacteria-in-wastewater
Article - 30/10/2018 Eucor – bringing the European Campus to life Enrolling at one university and being able to use the services of a total of five universities is unique in the European Research Area. A model project called Eucor - The European Campus offers students and young scientists this opportunity at universities in the Germany-France-Switzerland border triangle, which simultaneously acts as a borderless academic area for the sciences. https:////www.gesundheitsindustrie-bw.de/en/article/news/eucor-bringing-the-european-campus-to-life
Press release - 27/07/2018 KIT Takes the Next Step: Federal and State Ministries Determined to Push KIT’s Further Development To further support and develop the scientific capacity of Karlsruhe Institute of Technology (KIT), the federal and state governments are determined to take the courageous merger of 2009 to the next level. During their joint visit of KIT today, Federal Minister of Education and Research Anja Karliczek and the Baden-Württemberg Minister for Science, Research and the Arts Theresia Bauer agreed on the next steps. https:////www.gesundheitsindustrie-bw.de/en/article/press-release/kit-takes-the-next-step-federal-and-state-ministries-determined-to-push-kits-further-development
Alternative to animal experiments - 21/03/2018 Drug tests using miniature organs At present, potential new drugs have to be tested on animals before they can be used on humans. However, results obtained from animals are not always transferrable to the situation in humans, which is why researchers around the world have long been seeking alternatives. Miniature human organs that can be used to test the efficacy of potential human drugs might provide a solution.https:////www.gesundheitsindustrie-bw.de/en/article/news/drug-tests-using-miniature-organs
Article - 28/09/2017 Textile implant as herniated disc repair kit Repairing herniated discs is a clinical need that has still not been met. When the discomfort becomes unbearable, surgery can be performed and the intervertebral disc is generally removed. However, this can further reduce the patients’ quality of life. Scientists at DITF, in cooperation with the Spanish company NEOS Surgery S.L., have developed a textile-based device for treating herniated discs. The device is a minimally invasive “repair kit”…https:////www.gesundheitsindustrie-bw.de/en/article/news/textile-implant-as-herniated-disc-repair-kit
Article - 19/06/2017 Eric Gottwald: innovative 3D cell culture systems for pharmaceutical testing Realistic alternatives to animal testing are more in demand than ever, especially in the drug development field. One possible solution is 3D cell cultures that possess the characteristics of the tissue from which they originate. Such systems were already developed at the Karlsruhe Institute of Technology (KIT) many years ago. Due to the huge demand for such systems, Prof. Dr. Eric Gottwald and two of his colleagues founded a company called…https:////www.gesundheitsindustrie-bw.de/en/article/news/eric-gottwald-innovative-3d-cell-culture-systems-for-pharmaceutical-testing
Press release - 23/05/2017 TolerogenixX secures seed funding and completes Phase I clinical trial TolerogenixX GmbH has developed a patented and clinically tested cell therapy technique for individualised immunosuppression in transplant patients. The technique enables the targeted disabling of undesired reactions caused by the immune system’s defences. As a seed stage investor, High-Tech Gründerfonds (HTGF) will finance this innovative technique and the preparations for Phase II of the clinical trial, which begins in spring 2018. Further…https:////www.gesundheitsindustrie-bw.de/en/article/press-release/tolerogenixx-secures-seed-funding-and-completes-phase-i-clinical-trial
Article - 22/02/2017 MammaScreen – blood test for early detection of breast cancer The MammaScreen team from the University of Heidelberg Women’s Hospital has developed a blood test for diagnosing breast cancer. This new test can detect breast cancer at a very early stage. It works on women of all ages with tumours of any type and size. https:////www.gesundheitsindustrie-bw.de/en/article/news/mammascreen-blood-test-for-early-detection-of-breast-cancer
Article - 07/02/2017 Designer proteins as beacons of hope for pharmaceutical and biotechnological applications Proteins are the basic building blocks of cells. They tend to be biologically active in combination with many other proteins rather than as isolated entities. Such protein complexes play a key role in many vital processes in our bodies. An international team of researchers, including Professor Stefan Bräse and his team from the Karlsruhe Institute of Technology (KIT), has developed an innovative platform called MultiBacTAG that can be used to…https:////www.gesundheitsindustrie-bw.de/en/article/news/designer-proteins-as-beacons-of-hope-for-pharmaceutical-and-biotechnological-applications
Press release - 31/01/2017 Background Suppression for Super-resolution Light Microscopy Researchers of Karlsruhe Institute of Technology (KIT) have developed a new fluorescence microscopy method: STEDD (Stimulation Emission Double Depletion) nanoscopy produces images of highest resolution with suppressed background. The new method yields an enhanced image quality, which is advantageous when analyzing three-dimensional, densely arranged subcellular structures. STEDD, a further development of the STED method, is now presented in…https:////www.gesundheitsindustrie-bw.de/en/article/press-release/background-suppression-for-super-resolution-light-microscopy
Press release - 14/12/2016 amcure Raises €6 Million in Series B Financing and Expands Advisory Board Eggenstein-Leopoldshafen – 14 December 2016: amcure, a biopharmaceutical company developing first-in-class cancer therapeutics, today announced the closing of a Series B financing round amounting to a total of EUR 6 million.https:////www.gesundheitsindustrie-bw.de/en/article/press-release/amcure-raises-6-million-in-series-b-financing-and-expands-advisory-board
Company profile - 25/07/2016 300MICRONS: 3D cell culture solutions tailored to customer needs What happens in tissues and organs and how do they react to pharmaceutical substances? Three-dimensional cell cultures can reproduce reality far better than a single-cell layer can. With good reason. Reality is far from two-dimensional. A company called 300MICRONS GmbH develops films with tiny indentations that provide optimal conditions for cells to grow into 3D cell aggregates.https:////www.gesundheitsindustrie-bw.de/en/article/news/300microns-3d-cell-culture-solutions-tailored-to-customer-needs
Company profile - 05/07/2016 HS-Analysis GmbH – using digital histology to develop new drugs The idea of analysing tissue samples automatically sounds more of a pipe dream than anything else. However, it already happens. HS-Analysis GmbH's ability to interpret tissue samples automatically is driving new drug development a decisive step forward.https:////www.gesundheitsindustrie-bw.de/en/article/news/hs-analysis-gmbh-using-digital-histology-to-develop-new-drugs
Article - 16/06/2016 Microfluidic biofermenter mimics plant tissue It is estimated that as many as one million secondary plant metabolites can be used as medical agents. Plants produce these compounds to aid their growth and development as well as to discourage herbivores from eating them. However, it is still very difficult, or even impossible, to produce secondary plant metabolites industrially. Researchers from the Karlsruhe Institute of Technology (KIT) are now developing a microfluidic bioreactor to make…https:////www.gesundheitsindustrie-bw.de/en/article/news/microfluidic-biofermenter-mimics-plant-tissue
Article - 02/06/2016 DNA origami for decoding the language of biological cells Cells have their own language that they use to communicate with each other. They need this language to be able to form intact tissues and fulfil their specific functions in the body. If these signalling pathways are disrupted, metabolic processes will suffer and result in diseases. We know many “words” of the cellular language, i.e. signalling molecules that bind to specific surface receptors and thereby trigger chemical reactions inside the…https:////www.gesundheitsindustrie-bw.de/en/article/news/dna-origami-for-decoding-the-language-of-biological-cells
Article - 12/05/2016 Novel method for predicting the spatial structure of biomolecules Biomolecules can only fulfil their functions in the cell when they fold into a characteristic native three-dimensional structure. Knowing this structure is not only of paramount importance for basic research, but also for medicine and pharmacology. Scientists from the Karlsruhe Institute of Technology (KIT) have therefore developed a simple method to predict the three-dimensional structure of biomolecules from the analysis of readily available…https:////www.gesundheitsindustrie-bw.de/en/article/news/novel-method-for-predicting-the-spatial-structure-of-biomolecules
Article - 21/12/2015 Using a heart simulator for optimal therapy A realistic computer model of the human heart is expected to make treating heart diseases more effective: doctors will be able to test medicines and surgical techniques on the computer heart and determine the most effective therapy. Olaf Dössel, director of the Institute of Biomedical Engineering at the Karlsruhe Institute of Technology, believes that his team's heart model is among the top five in the world.https:////www.gesundheitsindustrie-bw.de/en/article/news/using-a-heart-simulator-for-optimal-therapy
Article - 08/06/2015 New construction kit for designing new proteins Protein building blocks with well-defined properties that can be assembled into new molecules with desired structures and functions are highly sought after in biotechnology and medicine. Birte Höcker, a biologist at the Max Planck Institute for Developmental Biology in Tübingen, is currently working on this in a project she calls “Protein Lego”.https:////www.gesundheitsindustrie-bw.de/en/article/news/new-construction-kit-for-designing-new-proteins
Dossier - 09/02/2015 Chemical tools for biological applications The boundaries between traditional scientific disciplines are becoming less and less distinct. Interdisciplinary cooperation is often required to study complex processes and biomolecular issues. Interdisciplinary cooperation is central to chemical biology, a scientific discipline that applies chemical substances, methods and tools to the study of biological systems ranging from the chemical synthesis of biologically active substances to the…https:////www.gesundheitsindustrie-bw.de/en/article/dossier/chemical-tools-for-biological-applications
Press release - 18/08/2014 Research Programme Bio-Economy: 11 projects at the University Stuttgart The use of sustainable raw materials is the focus of the new research programme bio-economy for which the Baden-Württemberg State Government is making 13 million Euros available. Of the total of 45 research projects recommended for funding 11 projects already approved are established at seven institutes at the University of Stuttgart these have a volume of two million Euros.https:////www.gesundheitsindustrie-bw.de/en/article/press-release/research-programme-bio-economy-11-projects-at-the-university-stuttgart
Press release - 15/07/2014 amcure Receives EUR 5 Million Funding for the Development of New Tumour Therapeutic Agents amcure GmbH, a spin-off from the Karlsruhe Institute of Technology (KIT), has closed a Series A financing deal amounting to a total of EUR 5 million. The funding comes from a consortium headed by LBBW Venture Capital, with participations from KfW, MBG Mittelständische Beteiligungsgesellschaft Baden-Wuerttemberg, S-Kap Beteiligungen Pforzheim, BioM AG as well as private investors. The company also receives subsidies from the German Ministry of…https:////www.gesundheitsindustrie-bw.de/en/article/press-release/amcure-receives-eur-5-million-funding-for-the-development-of-new-tumour-therapeutic-agents